Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton.
The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods.
Its segments include EksoHealth and EksoWorks..
Price and Volume | |
---|---|
Volume | |
Ten Day Average Volume | 140.9K |
Three Month Average Volume | 1.8M |
High Low | |
Fifty-Two Week High | 3.1285 USD |
Fifty-Two Week Low | 0.62 USD |
Fifty-Two Week High Date | 02 Jan 2024 |
Fifty-Two Week Low Date | 08 Sep 2023 |
Price and Volume | |
Current Price | 1.2 USD |
Beta | 1 |
Relative Price Change | |
Four Week Relative Price Change | 13.59% |
Thirteen Week Relative Price Change | -2.50% |
Twenty-Six Week Relative Price Change | -45.16% |
Fifty-Two Week Relative Price Change | 6.37% |
Year-to-Date Relative Price Change | -59.47% |
Price Change | |
One Day Price Change | 7.14% |
Thirteen Week Price Change | 4.35% |
Twenty-Six Week Price Change | -39.70% |
Five Day Price Change | 12.15% |
Fifty-Two Week Price Change | 33.29% |
Year-to-Date Price Change | -52.00% |
Month-to-Date Price Change | 14.29% |
Per Share Data | |
---|---|
Book Value | |
Book Value Per Share (Last Fiscal Year) | 0.849 USD |
Book Value Per Share (Most Recent Quarter) | 0.65382 USD |
Tangible Book Value Per Share (Last Fiscal Year) | 0.4905 USD |
Tangible Book Value Per Share (Most Recent Quarter) | 0.37351 USD |
EBITD | |
EBITD Per Share (Trailing Twelve Months) | -0.63278 USD |
Revenue | |
Revenue Per Share (Last Fiscal Year) | 1.31817 USD |
Revenue Per Share (Trailing Twelve Months) | 1.13203 USD |
Dividend | |
Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
Dividend Per Share (Trailing Twelve Months) | 0 USD |
Dividend Per Share (5 Year) | -99999.99 USD |
Earnings Per Share | |
Excluding Extraordinary Items (Last Fiscal Year) | -1.09598 USD |
Excluding Extraordinary Items (Trailing Twelve Months) | -0.79092 USD |
Normalized (Last Fiscal Year) | -1.09598 USD |
Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.09598 USD |
Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.79092 USD |
Including Extraordinary Items (Last Fiscal Year) | -1.09598 USD |
Including Extraordinary Items (Trailing Twelve Months) | -0.79092 USD |
Cash | |
Cash Per Share (Last Fiscal Year) | 0.58176 USD |
Cash Per Share (Most Recent Quarter) | 0.31907 USD |
Cash Flow Per Share (Last Fiscal Year) | -1.04363 USD |
Cash Flow Per Share (Trailing Twelve Months) | -0.66101 USD |
Free Cash Flow Per Share (Trailing Twelve Months) | -0.69449 USD |
Margins | |
---|---|
Cash Flow Revenue | |
Cash Flow Revenue (5 Year) | -96 |
Cash Flow Revenue (Trailing Twelve Months) | -61 |
Pretax Margin | |
Pretax Margin (Trailing Twelve Months) | -68.41% |
Pretax Margin (Last Fiscal Year) | -83.14% |
Pretax Margin (5 Year) | -104.24% |
Gross Margin | |
Gross Margin (Last Fiscal Year) | 49.67% |
Gross Margin (Trailing Twelve Months) | 51.83% |
Gross Margin (5 Year) | 51.93% |
Operating Margin | |
Operating Margin (Last Fiscal Year) | -82.67% |
Operating Margin (Trailing Twelve Months) | -66.52% |
Operating Margin (5 Year) | -112.80% |
Net Profit Margin | |
Net Profit Margin (Last Fiscal Year) | -83.14% |
Net Profit Margin (Trailing Twelve Months) | -68.41% |
Net Profit Margin (5 Year) | -104.24% |
Growth | |
---|---|
Book Value | |
Book Value Per Share (5 Year) | 5.49% |
Tangible Book Value (5 Year) | 23.46% |
Free Operating Cash Flow | |
Free Operating Cash Flow (5 Year) | -99,999.99% |
Revenue | |
Revenue Change MRQ vs 1 Year Ago | 5.25% |
Revenue Growth (3 Year) | 10.03% |
Revenue Change (Trailing Twelve Months) | 15.63% |
Revenue Per Share Growth | -13.84% |
Revenue Growth (5 Year) | 27.20% |
Capital Spending Debt | |
Capital Spending (5 Year) | 3.69% |
Total Debt (5 Year) | 3.93% |
Dividends | |
Dividend Growth (3 Year) | -99,999.99% |
Earnings Per Share | |
EPS Change MRQ vs 1 Year Ago | 57.26% |
EPS Change (Trailing Twelve Months) | 34.69% |
EPS Growth (3 Year) | -99,999.99% |
EPS Growth (5 Year) | -99,999.99% |
EBITDA | |
EBITDA (5 Year) | -99,999.99% |
EBITDA (5 Year Interim) | -99,999.99% |
Net Profit Margin | |
Net Profit Margin Growth (5 Year) | -99,999.99% |
Valuation | |
---|---|
Total Price to Book | |
Price to Tangible Book (Last Fiscal Year) | 3 |
Price to Tangible Book (Most Recent Quarter) | 3 |
Price to Free Cash Flow | |
Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
Net Debt | |
Net Debt (Most Recent Quarter) | -283,000 |
Net Debt (Last Fiscal Year) | -2,556,000 |
Price to Sales | |
Price to Sales (Last Fiscal Year) | 1 |
Price to Sales (Trailing Twelve Months) | 1 |
Price to Earnings | |
PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
PE Normalized (Last Fiscal Year) | -100,000 |
PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
Dividends | |
Dividend Yield (5 Year) | -99,999.99% |
Dividend Yield | -99,999.99% |
Current Dividend Yield | 0.00% |
Price to Book | |
Price to Book (Last Fiscal Year) | 1 |
Price to Book (Most Recent Quarter) | 2 |
Financial Strength | |
---|---|
Debt to Equity | |
Long Term Debt to Equity (Last Fiscal Year) | 38 |
Long Term Debt to Equity (Most Recent Quarter) | 36 |
Payout Ratio | |
Payout Ratio (Last Fiscal Year) | -99,999.99% |
Payout Ratio (Trailing Twelve Months) | -99,999.99% |
Quick Ratio | |
Quick Ratio (Last Fiscal Year) | 2 |
Quick Ratio (Most Recent Quarter) | 2 |
Enterprise Value | |
Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
Current Ratio | |
Current Ratio (Last Fiscal Year) | 2 |
Current Ratio (Most Recent Quarter) | 2 |
Free Cash Flow | |
Free Cash Flow (Last Fiscal Year) | -12,211,000 |
Free Cash Flow (Trailing Twelve Months) | -11,141,000 |
Net Interest Coverage | |
Net Interest Coverage (Last Fiscal Year) | -100,000 |
Net Interest Coverage (Trailing Twelve Months) | -24 |
Total Debt to Equity | |
Total Debt to Equity (Last Fiscal Year) | 48 |
Total Debt to Equity (Most Recent Quarter) | 46 |
Management Effectiveness | |
---|---|
Return on Assets | |
Return on Assets (Last Fiscal Year) | -43.53% |
Return on Assets (Trailing Twelve Months) | -40.75% |
Return on Assets (5 Year) | -43.63% |
Return on Equity | |
Return on Equity (Last Fiscal Year) | -79.89% |
Return on Equity (Trailing Twelve Months) | -83.20% |
Return on Equity (5 Year) | -84.64% |
Return on Investment | |
Return on Investment (Last Fiscal Year) | -57.89% |
Return on Investment (Trailing Twelve Months) | -57.60% |
Return on Investment (5 Year) | -57.67% |